Finoriq research workspace
Adaptive Biotechnologies Corp (ADPT) SEC Filings & Filing Highlights
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine. Review ADPT SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Company
- Adaptive Biotechnologies Corp (ADPT)
- Ticker
- ADPT
- Market Cap
- $3.5B
- Latest Price
- $21.85
- Industry
- Biotech & Pharma
Adaptive Biotechnologies Corp (ADPT) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Adaptive Biotechnologies Corp (ADPT).
| Event | Form | Date |
|---|---|---|
| Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offer...Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering | 8-K8.01 | 2026-06-22 |
| Adaptive Biotechnologies Corp: Securities issuanceThe disclosure set forth in Item 1.01 above is incorporated by reference into this Item 3.02. The Notes were issued to the initial purchase... | 8-K3.02 | 2026-06-22 |
| Termination of Material Definitive AgreementTermination of Material Definitive Agreement | 8-K1.02 | 2026-06-22 |
| 0% Convertible Senior Notes due 2031On June 22, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued $345 million in aggregate principal amount of 0% Convertible... | 8-K1.01 | 2026-06-22 |
| Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes OfferingAdaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering | 8-K8.01 | 2026-06-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.